Faricimab - Roche
Alternative Names: Faricimab-svoa; RG 7716; RO 6867461; VABYSMO; VabysmoLatest Information Update: 10 May 2024
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Genentech; Roche
- Class Bispecific antibodies; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
- Preregistration Diabetic retinopathy
- Phase III Angioid streaks; Choroidal neovascularisation
- Clinical Phase Unknown Polypoidal choroidal vasculopathy
Most Recent Events
- 09 May 2024 Roche intends to file a regulatory application for Myopic choriodial neovascularisation (intravitreous) in or after 2027 (Roche pipeline, May 2024)
- 06 Mar 2024 Phase-III clinical trials in Choroidal neovascularisation in Taiwan, Germany, Hong Kong, Poland, South Korea, China, Australia (Intravitreous) (NCT06176352) (EudraCT2023-506707-25-00)
- 01 Feb 2024 Efficacy data from the phase III BALATON trial in Retinal oedema released by Roche